Caris Life Sciences 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Caris Life Sciences reported 3rd quarter 2026 revenue of $275.4 million, up 27% year over year, and approximately 61,500 clinical therapy selection cases, up 21%.
- Molecular profiling services revenue was $262.7 million, up 27%, and pharma research and development services revenue was $12.7 million, up 37%.
- Blended ASP including prior period collections was $4,272, up 5% year over year; base ASP was approximately $4,000, up 19%.
- Gross margin was 66%; GAAP net income was $15.3 million and adjusted EBITDA was $44.4 million, the 6th consecutive quarter of positive adjusted EBITDA.
- Free cash flow was negative $39.7 million in the quarter, including $17.5 million in capital expenditures; cash and investments were $769.2 million at quarter end.
- The company repurchased approximately $10 million of additional stock under its authorized share repurchase program in Q3.
- Caris ended the quarter with 325 commercial team members, compared with 290 at the end of the 2nd quarter and 270 at the end of the 1st quarter; more than 75% of orders were placed through EMR and portal channels.
- Caris Assure therapy response monitoring launched in the quarter, and Caris Confirm, a tumor-informed whole genome MRD assay, is planned for launch in December.
- The company reported a dataset of more than 1.2 million profiled cases and more than 1,300 publications and manuscripts.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Good afternoon, everyone, and welcome to the Caris Life Sciences third quarter 2026 earnings call. My name is Lisa, and I will be your conference operator today. All participants are on a listen-only mode. After the prepared remarks, there will be a question-and-answer session. As a reminder, this call is being recorded. I would now like to hand it over to Russ Denton at Caris. Please go ahead. Thank you.
Earlier today, Caris Life Sciences released financial results for the quarter ended September 30, 2026. Joining from Caris today are David D. Halbert, our founder, chairman, and CEO, David Spetzler, our president, Brian Brille, our vice chairman and EVP, and Luke Power, our CFO. Before we begin, I'd like to remind you that during this call, management will make forward-looking statements within the meaning of federal securities laws. These statements are based on management's current expectations and involve risks and uncertainties that could cause actual results to materially differ from those anticipated. For a discussion of the factors that could affect our future results, please refer to our SEC filings. We undertake no obligation to update these statements except as required by law. This call will also include a discussion of non-GAAP financial measures, which are adjusted to exclude certain specified items.
The reconciliations of these non-GAAP measures to the most directly comparable GAAP measures are provided in today's earnings release. A copy of today's presentation materials can be found on our investor relations website. I'll now turn the call over to our founder, chairman, and CEO, David D.
Halbert. David? Thanks, Russ, and thanks everyone for joining.
This was another record quarter for us with volume up 21% to 61,500 cases, and our revenue grew 27% to $275 million. What I like most about these numbers is that they are the continued result of a plan. At the start of the year, we realigned and expanded the sales organization and invested in the lab ahead of the demand we expected. Since then, we have delivered two consecutive quarters of acceleration, and this quarter's year-over-year volume growth is the strongest we've posted in over a year, and we expect that trend to continue into the fourth quarter. We have also taken the same approach with the product pipeline, where we have launched four products so far this year, and by year-end, we'll launch our fifth, Caris Confirm, our Whole Genome MRD assay, and complete our comprehensive approach across the patient journey.
And comprehensive isn't just a slogan for us. You can see that as recently as September, where we launched a new version of Caris Assure for therapy selection that reads the therapy-relevant genes at 40,000X depth and takes our RNA reads past 600 million. We always say deeper, not cheaper, as the depth and breadth of an assay is what matters, allowing us to continue to drive the science forward. I made the decision to take the company to whole exome, Whole Transcriptome back in 2018, and that has produced our exome platform, which includes MI Cancer Seek, Caris Assure for therapy selection, and now Caris Assure for monitoring. We're taking the same approach for our next phase with expanding to Whole Genome, and you can see this in our approach for early-stage detection, therapy selection, and MRD.
Now, with regards to Caris Detect, I told you in August that the interest had run ahead of even my own expectations, and it has, but we're not going to chase it by overspending. We're building this deliberately. We've launched two national campaigns with Kevin Costner and Jordan Spieth, both of whom I've had the pleasure of sitting down with to discuss their reasons for participating in our ads, and we will continue to roll out and expand these into new markets in Q4 and beyond. Also, our next campaign will be focused on educating the public regarding performance and understanding of stage. The whole idea behind early detection is to catch the cancer while it is still treatable before it spreads, meaning early stage 1 and 2.
After that, it's likely not to be treatable, and sadly, the tests being marketed currently use a technology called methylation, and a methylation-only approach doesn't work in early stages for most cancers, and it's unclear why someone would order one, like a poop test for one cancer when you could take a blood test for over 50 different cancers. That's exactly why we built Caris Detect on Whole Genome. It's designed to find cancer at those early treatable stages. We'll keep building it that way, and as David will discuss in a few minutes, we are also going to continue to demonstrate our best-in-class performance by expanding our ACHIEVE program. So I feel great about where we are. We went deeper when others went cheaper. We built a plan that is working, and we're funding every bit of it ourselves while we manage the P&L.
We'll keep making decisions the way we always have, by the mom rule. If it were my mom, I'd want her to get the most complete answer possible. Every patient deserves that, and that's how we'll make precision medicine a reality.
Brian, over to you. Thanks, David, and thank you all for joining our third quarter 2026 earnings call.
This is another record quarter and an extremely important quarter for Caris for many reasons. First, the commercial strategy and investment is working and is delivering accelerating volume growth. In addition, the MCED launch is advancing well with important new potential channel partners who are excited about Caris Detect's technology, and specifically early-stage sensitivity. We are also announcing our entry into the MRD and monitoring market with the launch this quarter of Caris Assure Therapy Response Monitoring. This will be followed by the upcoming launch in December of Caris Confirm for MRD. With the launch of these products, we now have the best molecular technology across the entire cancer care continuum. We did all of this while delivering sustained growth and profitability. Our commercial strategy and investment program is successful and delivering results.
In the third quarter, we completed approximately 61,500 clinical cases, up 21% year-over-year. This is our second consecutive quarter of accelerating growth, up from 15% in the first quarter and 18% in the second quarter. We expect the momentum to continue as the commercial platform expands and new members of the sales force season. With respect to the pipeline, Caris Detect launched this summer, and Caris Assure Therapy Response Monitoring launched this quarter. As a result, as illustrated on slide four, our platform now spans the entire continuum of care, including therapy selection in tissue and liquid biopsy with MI Cancer Seek and Caris Assure, respectively, therapy selection in hematological cancers with ChromoSeq, Caris Detect for MCED, Caris Assure for monitoring, and Caris Confirm for MRD. We are very excited about the initial assay in our MRD product suite, Caris Assure for monitoring.
Monitoring is highly important clinically to provide oncologists a quantitative measure of treatment efficacy. The elegance of our technology is that it utilizes the same product platform as Caris Assure Liquid Biopsy, with the same whole exome 23,000 gene platform, and the same liquid workflow our customers already use for therapy selection. The serial blood draws using Assure provide us with a consistent longitudinal view of cancer progression during treatment, and will add another valuable edge to our clinical genomic dataset. Caris Confirm, our tumor-informed Whole Genome approach to MRD, is on track to launch this December. Our clinical customers are excited about the launch of both of these products across the continuum of care. We get significant leverage from our commercial channel since each of these MRD products will be provided to the same institutions, the same oncologists, and the same patients that use us for therapy selection.
Finally, our MCED platform, Caris Detect, has been the vision of our founder for many years, and the recent launch of Detect continues to build momentum. The unique multi-omic approach of Detect has produced exceptional early-stage sensitivity and is being well received by the market. The channel partner conversations from digital platforms to concierge medicine groups are going extremely well. We launched our first consumer campaign in the third quarter featuring Kevin Costner, and our second recently with Jordan Spieth, to raise the awareness of the importance of early-stage cancer detection and of Caris Detect. We are excited about our data and studies, and Spetz will outline that, including the expanded ACHIEVE program. Our philosophy continues to be a long-term strategic orientation, to develop the best, most comprehensive offerings on the market, and to pursue that innovation while maintaining financial strength.
We had a strong third quarter with total revenues increasing 27% year-over-year to $275 million. As illustrated on slide seven, this is driven by molecular profiling services revenues of $262.7 million, also up 27%. I would point out that the prior year quarter also included a significant amount of true-ups, and as a result, on a pro forma basis, revenue grew approximately 45% year-over-year. In summary, we had a very productive quarter, illustrated by the quarter highlights on slide six. Strong revenue performance combined with the operating leverage in our model continued to produce positive financial results while we step up investment, including revenue growth of 27%, driven by clinical volume growth of 21%, and a blended ASP of $4,272, up 5% year-over-year. On a pre-true-up basis, our blended ASP was approximately $4,000, up 19%.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
19 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
